$PALI
PALISADE BIO, INC.

2021 Q1 Form 10-K Financial Statement

#000117184321001965 Filed on March 22, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q4 2020
Revenue $0.00 $13.52K
YoY Change -12.17%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.720M $3.990M $8.670M
YoY Change 32.31% 191.24% 88.89%
% of Gross Profit
Research & Development $471.1K $410.0K $2.018M
YoY Change -32.4% -46.75% -50.3%
% of Gross Profit
Depreciation & Amortization $10.00K $10.00K $29.00K
YoY Change -66.67% -66.67% -40.82%
% of Gross Profit
Operating Expenses $1.954M $4.400M $9.297M
YoY Change -2.13% 105.61% 7.52%
Operating Profit -$1.954M -$9.297M
YoY Change -1.83% 7.71%
Interest Expense $1.711M -$20.00K $235.0K
YoY Change 66243.54% -122.22% 2534.53%
% of Operating Profit
Other Income/Expense, Net -$2.076M $0.00 -$1.025M
YoY Change -62.83% -466.02%
Pretax Income -$2.290M -$4.420M -$16.27M
YoY Change -69.79% 116.67% 94.85%
Income Tax $1.000K
% Of Pretax Income
Net Earnings -$4.030M -$4.420M -$10.32M
YoY Change 69.04% 116.67% 23.59%
Net Earnings / Revenue -76346.15%
Basic Earnings Per Share -$3.72
Diluted Earnings Per Share -$792.4K -$1.529M -$3.72
COMMON SHARES
Basic Shares Outstanding 17.30M 17.30M 2.774M
Diluted Shares Outstanding 2.774M

Balance Sheet

Concept 2021 Q1 2020 Q4 2020
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.560M $10.53M $10.53M
YoY Change -34.6% 106.07% 106.07%
Cash & Equivalents $615.0K $713.0K $10.53M
Short-Term Investments
Other Short-Term Assets $2.170M $2.240M $2.240M
YoY Change 429.27% 339.22% 339.22%
Inventory
Prepaid Expenses $1.309M $1.400M
Receivables $25.26K $59.00K $120.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $8.756M $896.0K $12.88M
YoY Change -16.32% -84.13% 127.96%
LONG-TERM ASSETS
Property, Plant & Equipment $7.243K $5.000K $10.00K
YoY Change -76.73% -87.82% -75.0%
Goodwill
YoY Change
Intangibles $141.6K $147.1K
YoY Change -78.2% -78.0%
Long-Term Investments
YoY Change
Other Assets $10.00K $10.00K $10.00K
YoY Change -66.67% -95.65% -95.65%
Total Long-Term Assets $159.3K $2.123M $170.0K
YoY Change -82.23% 126.57% -81.72%
TOTAL ASSETS
Total Short-Term Assets $8.756M $896.0K $12.88M
Total Long-Term Assets $159.3K $2.123M $170.0K
Total Assets $8.915M $3.019M $13.05M
YoY Change -21.53% -54.15% 98.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $520.0K $2.537M $650.0K
YoY Change -45.83% 209.39% -20.73%
Accrued Expenses $320.0K $2.740M $2.320M
YoY Change 146.15% 1857.14% 1557.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $1.047M
YoY Change
Total Short-Term Liabilities $1.015M $8.082M $3.210M
YoY Change -14.44% 559.89% 163.11%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $94.00K $0.00
YoY Change
Other Long-Term Liabilities $170.0K $80.00K $80.00K
YoY Change -15.0% -65.22% -65.22%
Total Long-Term Liabilities $170.0K $94.00K $80.00K
YoY Change -15.0% -59.13% -65.22%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.015M $8.082M $3.210M
Total Long-Term Liabilities $170.0K $94.00K $80.00K
Total Liabilities $1.186M $10.12M $3.280M
YoY Change -14.21% 594.01% 124.66%
SHAREHOLDERS EQUITY
Retained Earnings -$240.5M -$68.03M
YoY Change 4.78% -69.35%
Common Stock $28.83K $28.00K
YoY Change -69.43% -27.58%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$20.06M -$16.60M $9.770M
YoY Change
Total Liabilities & Shareholders Equity $8.915M $3.019M $13.05M
YoY Change -21.53% -54.15% 98.33%

Cashflow Statement

Concept 2021 Q1 2020 Q4 2020
OPERATING ACTIVITIES
Net Income -$4.030M -$4.420M -$10.32M
YoY Change 69.04% 116.67% 23.59%
Depreciation, Depletion And Amortization $10.00K $10.00K $29.00K
YoY Change -66.67% -66.67% -40.82%
Cash From Operating Activities -$1.250M -$2.200M -$4.768M
YoY Change -25.49% 7.32% -34.29%
INVESTING ACTIVITIES
Capital Expenditures $6.000K
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$6.000K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.175M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.152M 0.000 1.890M
YoY Change -82.53% -100.0% -71.32%
NET CHANGE
Cash From Operating Activities -1.250M -2.200M -4.768M
Cash From Investing Activities -6.000K
Cash From Financing Activities 1.152M 0.000 1.890M
Net Change In Cash -98.00K -2.200M -2.884M
YoY Change -101.99% 0.46% 329.04%
FREE CASH FLOW
Cash From Operating Activities -$1.250M -$2.200M -$4.768M
Capital Expenditures $6.000K
Free Cash Flow -$4.774M
YoY Change -34.2%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q2 dei Entity Public Float
EntityPublicFloat
12444149
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001357459
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
17295703
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Entity Registrant Name
EntityRegistrantName
Seneca Biopharma, Inc.
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020 dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value
CY2020 dei Trading Symbol
TradingSymbol
snca
CY2020Q4 snca Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
649345
CY2019Q4 snca Accounts Payable And Accrued Expenses Excluding Accrued Bonuses
AccountsPayableAndAccruedExpensesExcludingAccruedBonuses
824406
CY2020Q4 snca Accrued Severance
AccruedSeverance
2300000
CY2019 snca Additional Research And Development Expense Due To Modifications
AdditionalResearchAndDevelopmentExpenseDueToModifications
102000
CY2020 snca Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
60000
CY2019 snca Cost Reimbursements From Sbir Grant As Offset To Research And Development Expenses
CostReimbursementsFromSBIRGrantAsOffsetToResearchAndDevelopmentExpenses
459000
CY2020 snca Effective Income Tax Rate Reconciliation Change In Fair Value Of Liability Classified Warrants Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfLiabilityClassifiedWarrantsPercent
0
CY2019 snca Effective Income Tax Rate Reconciliation Change In Fair Value Of Liability Classified Warrants Percent
EffectiveIncomeTaxRateReconciliationChangeInFairValueOfLiabilityClassifiedWarrantsPercent
-0.016
CY2020 snca Effective Income Tax Rate Reconciliation Warrant Inducement Expense Percent
EffectiveIncomeTaxRateReconciliationWarrantInducementExpensePercent
0.09
CY2019 snca Effective Income Tax Rate Reconciliation Warrant Inducement Expense Percent
EffectiveIncomeTaxRateReconciliationWarrantInducementExpensePercent
0
CY2020 snca Increase Decrease In Lease And Other Noncurrent Liabilities
IncreaseDecreaseInLeaseAndOtherNoncurrentLiabilities
-38211
CY2019 snca Increase Decrease In Lease And Other Noncurrent Liabilities
IncreaseDecreaseInLeaseAndOtherNoncurrentLiabilities
-34572
CY2020 snca Increase Decrease In Rou And Other Assets
IncreaseDecreaseInROUAndOtherAssets
-24537
CY2019 snca Increase Decrease In Rou And Other Assets
IncreaseDecreaseInROUAndOtherAssets
-39643
CY2020Q4 snca Operating Lease Rightofuse Asset And Other Assets Noncurrent
OperatingLeaseRightofuseAssetAndOtherAssetsNoncurrent
10439
CY2019Q4 snca Operating Lease Rightofuse Asset And Other Assets Noncurrent
OperatingLeaseRightofuseAssetAndOtherAssetsNoncurrent
227036
CY2020 snca Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
11150318
CY2019 snca Proceeds From Issuance Of Common Stock Net
ProceedsFromIssuanceOfCommonStockNet
6552842
CY2020Q4 snca Short Term Debt And Other Liabilities Current
ShortTermDebtAndOtherLiabilitiesCurrent
CY2019Q4 snca Short Term Debt And Other Liabilities Current
ShortTermDebtAndOtherLiabilitiesCurrent
264665
CY2019 snca Stock And Warrants Issued During Period From Capital Raises Value Net
StockAndWarrantsIssuedDuringPeriodFromCapitalRaisesValueNet
6552842
CY2020 snca Stock And Warrants Issued During Period From Capital Raises Value Net
StockAndWarrantsIssuedDuringPeriodFromCapitalRaisesValueNet
4434354
CY2019 snca Stock Issued During Period Value Rsu And Option Exercises Net Of Forfeitures
StockIssuedDuringPeriodValueRSUAndOptionExercisesNetOfForfeitures
CY2020 snca Stock Issued During Period Value Rsu And Option Exercises Net Of Forfeitures
StockIssuedDuringPeriodValueRSUAndOptionExercisesNetOfForfeitures
CY2019 snca Stock Issued During Period Value Rounding Adjustment Related To Reverse Stock Split
StockIssuedDuringPeriodValueRoundingAdjustmentRelatedToReverseStockSplit
CY2020 snca Stock Issued During Period Value Stock And Inducement Warrants For Warrant Exercises
StockIssuedDuringPeriodValueStockAndInducementWarrantsForWarrantExercises
12352252
CY2019 snca Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
236
CY2020 snca Stock Issued During Period Value Warrant Exercised
StockIssuedDuringPeriodValueWarrantExercised
3531694
CY2020 snca Warrant Inducement And Other Expense
WarrantInducementAndOtherExpense
5620089
CY2019 snca Warrant Inducement And Other Expense
WarrantInducementAndOtherExpense
277906
CY2020 snca Warrant Inducement Expense
WarrantInducementExpense
5620089
CY2019 snca Warrant Inducement Expense
WarrantInducementExpense
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
116279
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
21064
CY2020Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
2322241
CY2019Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
135686
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
905180
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
950417
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-734
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-6186
CY2020 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P7Y109D
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
247836057
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
227067058
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
880789
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
584991
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
584991
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
880789
CY2020 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
63000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5114917
CY2019 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
95000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6400000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7300000
CY2020 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2019 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
CY2020Q4 us-gaap Assets
Assets
13049144
CY2019Q4 us-gaap Assets
Assets
6583889
CY2020Q4 us-gaap Assets Current
AssetsCurrent
12880796
CY2019Q4 us-gaap Assets Current
AssetsCurrent
5646881
CY2020Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
835483
CY2019Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10529244
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5114917
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
5787110
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
10554519
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5439602
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-672193
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
17295703
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3866457
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
17295703
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3866457
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
172957
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
38665
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16261368
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-8357424
CY2020 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2019 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2020 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2019 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2020 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-192953
CY2019 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
-545792
CY2020 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
CY2019 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
0
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-2086693
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
455994
CY2020 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
2086693
CY2019 us-gaap Deferred Other Tax Expense Benefit
DeferredOtherTaxExpenseBenefit
-455994
CY2020 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
-1893740
CY2019 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
1001786
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
44598560
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
46685253
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
40897678
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
43190604
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
1377275
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Other
DeferredTaxAssetsTaxCreditCarryforwardsOther
889372
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2323607
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2605277
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
44598560
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46685253
CY2020 us-gaap Depreciation
Depreciation
29000
CY2019 us-gaap Depreciation
Depreciation
49000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
92272
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
143859
CY2020 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
9298
CY2019 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
499138
CY2020Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
75298
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
84596
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.80
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-1185
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6018
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.128
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.055
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.038
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.064
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.26
CY2019 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.288
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.05
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.053
CY2020 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y73D
CY2020Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
530000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
191330
CY2019Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1337507
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
18000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
18000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
18000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
18000
CY2020Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
18000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
338463
CY2019Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
2006443
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
147133
CY2019Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
668936
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8670612
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4585638
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-105043
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-15741
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
95215
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-272993
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
2186555
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
135686
CY2020 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
5508
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-47414
CY2020 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1024494
CY2019 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
142310
CY2020 us-gaap Interest Expense
InterestExpense
14015
CY2019 us-gaap Interest Expense
InterestExpense
8920
CY2020 us-gaap Interest Paid Net
InterestPaidNet
14015
CY2019 us-gaap Interest Paid Net
InterestPaidNet
8920
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
33532
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
67731
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
147133
CY2019Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
668936
CY2020 us-gaap Lease Cost
LeaseCost
113100
CY2019 us-gaap Lease Cost
LeaseCost
108100
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
195300
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
58400
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
14600
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
62100
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
60200
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
36300
CY2020Q4 us-gaap Liabilities
Liabilities
3281228
CY2019Q4 us-gaap Liabilities
Liabilities
1457896
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13049144
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6583889
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3205930
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1224757
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
234344
CY2019Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14465916
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6589505
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9025129
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7255680
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-8351651
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-16266820
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5591274
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
280043
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
148543
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
204300
CY2020Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
158000000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-5773
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
5452
CY2020 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
5452
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020 us-gaap Open Tax Year
OpenTaxYear
2017 2018 2019 2020
CY2020 us-gaap Operating Expenses
OperatingExpenses
10689066
CY2019 us-gaap Operating Expenses
OperatingExpenses
8647088
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-10675546
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-8631694
CY2020 us-gaap Operating Lease Cost
OperatingLeaseCost
113100
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
171000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
113100
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
194200
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
CY2019 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-5773
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
7000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
200000
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
200000
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
200000
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
200000
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
2000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1399790
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
510900
CY2020 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
CY2019 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
414320
CY2020 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3547894
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
236
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
915956
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
991453
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10776
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
41036
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
362176
CY2020 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
232296
CY2019 us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
377893
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2018454
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4061450
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238242364
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-221975544
CY2020 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
13520
CY2019 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15394
CY2019 us-gaap Sublease Income
SubleaseIncome
86100
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
584991
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
880789
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
6700000
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
812742
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
16.42
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
160750
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1686466
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.52
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.45
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
438650
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
271660
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1797376
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.80
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
61.83
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
23.82
CY2020 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.62
CY2020Q4 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
1797376
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
182771
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y255D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y292D
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
500000
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
671100
CY2020 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
CY2020 us-gaap Stock Issued During Period Value Restricted Stock Award Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardForfeitures
CY2019 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6049550
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
5125993
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
9767916
CY2020 us-gaap Sublease Income
SubleaseIncome
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" font-size: 10pt; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white"><div style="display: inline; text-decoration: underline;">Use of Estimates</div></div></div> <div style=" font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><div style="display: inline; background-color: white">The preparation of consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The consolidated financial statements include significant estimates for the expected economic life and value of our licensed technology and related patents, our net operating loss and related valuation allowance for tax purposes, the fair value of our liability classified warrants and our share-based compensation related to employees and directors, consultants and advisors, among other things. Because of the use of estimates inherent in the financial reporting process, actual results could differ significantly from those estimates.</div></div></div></div></div></div></div></div>
CY2020 us-gaap Variable Lease Cost
VariableLeaseCost
CY2019 us-gaap Variable Lease Cost
VariableLeaseCost
23200
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13869272
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
2197434

Files In Submission

Name View Source Status
0001171843-21-001965-index-headers.html Edgar Link pending
0001171843-21-001965-index.html Edgar Link pending
0001171843-21-001965.txt Edgar Link pending
0001171843-21-001965-xbrl.zip Edgar Link pending
clinicprog.jpg Edgar Link pending
exh_2101.htm Edgar Link pending
exh_2301.htm Edgar Link pending
exh_311.htm Edgar Link pending
exh_312.htm Edgar Link pending
exh_321.htm Edgar Link pending
exh_322.htm Edgar Link pending
f10k_031521p.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snca-20201231.xml Edgar Link completed
snca-20201231.xsd Edgar Link pending
snca-20201231_cal.xml Edgar Link unprocessable
snca-20201231_def.xml Edgar Link unprocessable
snca-20201231_lab.xml Edgar Link unprocessable
snca-20201231_pre.xml Edgar Link unprocessable